TITLE

REDUCTION OF ISCHEMIC CORONARY HEART DISEASE BY CHONDROITIN SULFATE A

AUTHOR(S)
Morrison, Lester M.
PUB. DATE
March 1971
SOURCE
Angiology;Mar1971, Vol. 22 Issue 3, p165
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
1. The acid mucopolysaccharide, chondroitin sulfate A (CSA), which inhibited experimentally induced atherosclerosis in squirrel monkeys, rabbits, rats, and thromboses in monkeys, dogs, rabbits, rats and humans, was administered orally in tablet form to 60 patients with demonstrable ischemic coronary artery heart disease (ICD). Dosage ranged from an initial 10 gm. to 1.5 gm. daily for a period of four years. No toxic effects were noted and the medication was well tolerated. 2. These 60 CSA-treated patients were compared with a similar group of 60 control patients with demonstrable ICD. 3. At the end of four years in the CSA-treated group of 60 patients, 6 coronary incidents occurred. The surviving patients of this group have not required treatment or hospital admission for acute cardiac symptoms or recurrent illness. 4. After four years, 36 coronary incidents occurred in the 60 patient control group. Present ratio of coronary incidents in CSA-treated patients vs. non-CSA-treated patient controls is 6:36, or a ratio of 1:6. 5. A summation is presented of ten biological properties demonstrated for CSA which may in part account for the reduction of mortality and morbidity rates in patients with ischemic coronary disease of the heart treated with CSA over a four year period. 6. Long term statistically designed studies of CSA treatment for the prevention and treatment of coronary heart disease in a large group of patients are suggested as a result of current findings in experimental and human ischemic coronary heart disease.
ACCESSION #
16365819

 

Related Articles

  • Secondary prevention therapy in patients with coronary artery disease. Amsterdam, Ezra A.; Dhond, Milind // Formulary;Feb98, Vol. 33 Issue 2, p120 

    Discusses the efficacy of secondary prevention by risk factor modification and by drugs in reducing cardiac events in patients with clinically documented coronary artery disease (CAD). Guidelines for assessing coronary risk factors and pursuing therapeutic goals; Drugs found to have significant...

  • The DECLINE and RISE of CORONARY HEART DISEASE: Understanding Public Health Catastrophism. Jones, David S.; Greene, Jeremy A. // American Journal of Public Health;Jul2013, Vol. 103 Issue 7, p1207 

    The decline of coronary heart disease mortality in the United States and Western Europe is one of the great accomplishments of modern public health and medicine. Cardiologists and cardiovascular epidemiologists have devoted significant effort to disease surveillance and epidemiological modeling...

  • The DECLINE and RISE of CORONARY HEART DISEASE: Understanding Public Health Catastrophism. Jones, David S.; Greene, Jeremy A. // American Journal of Public Health;Jul2013, Vol. 103 Issue 7, p1207 

    The decline of coronary heart disease mortality in the United States and Western Europe is one of the great accomplishments of modern public health and medicine. Cardiologists and cardiovascular epidemiologists have devoted significant effort to disease surveillance and epidemiological modeling...

  • A wider role for a cholesterol drug. Rogers, Adam // Newsweek (Atlantic Edition);06/08/98 (Atlantic Edition), Vol. 131 Issue 23, p75 

    Reports that a drug used to treat people with coronary heart disease can also prevent illness in healthy people. Publication of a study in the Journal of the American Medical Association of the effect of lovastatin; Details of the study; Cost of treatment with the drug.

  • A wider role for a cholesterol drug. Rogers, Adam // Newsweek (Pacific Edition);06/08/98 (Pacific Edition), Vol. 131 Issue 23, p65 

    Reports that a drug used to treat people with coronary heart disease can also prevent illness in healthy people. Publication of a study in the Journal of the American Medical Association of the effect of lovastatin; Details of the study; Cost of treatment with the drug.

  • A wider role for a cholesterol drug. Rogers, Adam // Newsweek;6/8/1998, Vol. 131 Issue 23, p58 

    Reports that a drug used to treat people with coronary heart disease can also prevent illness in health people. Publication of a study in the Journal of the American Medical Association; Details of the study; Cost of treatment with the drug.

  • Almanac 2013–stable coronary artery disease. Islam, Shahed; Timmis, Adam // Romanian Journal of Cardiology;2014, Vol. 24 Issue 1, p15 

    The article reviews several articles related to coronary artery disease, including one which discusses the decline of coronary heart disease, another on the diagnosis of stable coronary artery disease, and one on the prevention of stable coronary disease.

  • The ACTonHEART study: rationale and design of a randomized controlled clinical trial comparing a brief intervention based on Acceptance and Commitment Therapy to usual secondary prevention care of coronary heart disease. Spatola, Chiara A. M.; Gian Mauro^Manzoni; Castelnuovo, Gianluca; Malfatto, Gabriella; Facchini, Mario; Goodwin, Christina L.; Baruffi, Matteo; Molinari, Enrico // Health & Quality of Life Outcomes;2014, Vol. 12 Issue 1, p1 

    Background Modifiable risk factors, including life-style habits and psychological variables, have been increasingly demonstrated to have an important role in influencing morbidity and mortality in cardiovascular patients, and to account for approximately 90% of the population risk for cardiac...

  • APOC3: Triglycerides do matter. Hassan, Mohamed // Global Cardiology Science & Practice;2014, Vol. 2014 Issue 4, p30 

    The article discusses the study which examines whether apolipoprotein C3 (APOC3) loss-of-function mutation lowers the risk of coronary heart disease (CHD). The study involved 3,734 elegible participants whose exome were sequenced. It found that regulating APOC3 may an important therapeutic...

  • Understanding coronary disease illness beliefs and patients’ activation. Santo, K.; Kirkendall, S.; Chow, C.; Rich, A.; Redfern, J. // Heart, Lung & Circulation;2015 Supplement 3, Vol. 24, pS458 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics